Comparison of Enoxaparin and Rivaroxaban in the Prophylaxis of Deep Venous Thrombosis in Arthroplasty

Basit Öğe Kaydı
dc.authorid0000-0003-3416-5666
dc.authorwosidsari, abdulkadir/AAF-3143-2021
dc.authorwosidsari, abdulkadir/ABH-3293-2021
dc.contributor.authorÇiçek, Necati
dc.contributor.authorAğır, İsmail
dc.contributor.authorTosun, Haci Bayram
dc.contributor.authorUludag, Abuzer
dc.contributor.authorSarı, Abdulkadir
dc.date.accessioned2022-05-11T14:36:16Z
dc.date.available2022-05-11T14:36:16Z
dc.date.issued2021
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Ortopedi ve Travmatoloji Ana Bilim Dalı
dc.description.abstractBackground. Pulmonary embolism is a serious early complication of arthroplasty procedures that can develop after deep venous thrombosis. The present study aimed to compare rivaroxaban and enoxaparin in terms of preventing DV and PE, and also in this study, we compared the complications due to these drugs in patients undergoing elective arthroplasty. Materials and Methods. 214 patients were divided into three groups based on their treatment regimens. In group I, enoxaparin was used, in group II, rivaroxaban was used, and in group III, enoxaparin was used throughout hospitalization, and after hospital discharge, rivaroxaban was used. These three groups were compared according to the occurrence of deep venous thrombosis, pulmonary embolism, and major and minor complications. Results. Major postoperative complications occurred in 5, 15, and 6 patients in group I, II, and III, respectively. Minor postoperative complications occurred in 10, 24, and 11 patients in group I, II, and III, respectively. No significant difference was found among the three groups. Deep venous thrombosis or pulmonary embolism was not observed in any patient. Conclusion. Rivaroxaban was found to be as effective as enoxaparin in the prevention of deep venous thrombosis and other complications after arthroplasty. Moreover, oral rivaroxaban provided greater ease of use compared to subcutaneous enoxaparin. Based on these findings, we consider that rivaroxaban could be an effective alternative to enoxaparin.
dc.identifier.doi10.1155/2021/2945978
dc.identifier.issn2090-2840
dc.identifier.issn2090-2859
dc.identifier.pmid34824871
dc.identifier.urihttps://doi.org/10.1155/2021/2945978
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8424
dc.identifier.volume2021
dc.identifier.wosWOS:000725271900001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.institutionauthorSarı, Abdulkadir
dc.language.isoen
dc.publisherHindawi Ltd
dc.relation.ispartofEmergency Medicine International
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTotal Hip
dc.subjectPulmonary-Embolism
dc.subjectVein Thrombosis
dc.subjectThromboembolism
dc.subjectPrevention
dc.subjectFondaparinux
dc.titleComparison of Enoxaparin and Rivaroxaban in the Prophylaxis of Deep Venous Thrombosis in Arthroplasty
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
8424.pdf
Boyut:
1.13 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Tıp Fakültesi Koleksiyonu